

Stereoselective Allylic Transposition by means of Allylic *n*-Pentenyl Ethers


Khadija Addi, Troels Skrydstrup, Michel Bénéchie and Françoise Khuong-Huu*

CNRS, Institut de Chimie des Substances Naturelles, 91198 Gif-sur-Yvette, France.

Abstract: Stereospecific formation of optically active tetrahydrofurans and dihydropyrans was obtained via an allylic rearrangement by means of allylic *n*-pentenyl ethers.

In our synthetic programme directed towards natural products, we were recently faced with the problem of having to perform an allylic transposition of 1, with the stereospecific introduction of the C(4)-hydroxy group *anti* to the C(3)-methyl in 2 (Scheme 1).

Scheme 1




We anticipated that assistance from the C(2)-hydroxyl of 1 could be made by intramolecular cyclisation of its corresponding carbonate and with a suitable leaving group X. However, as presented in 1 (Y=H), such an approach could possibly lead to an undesired mixture of epimers 2 and 3. On the other hand, by installation of a removable ligand in 1 (Y≠H), 1,3-allylic strain¹ would be imposed, forcing 1 into the conformation as indicated in Scheme 1, and thus favouring attack on the required α -face. In order to promote this cyclization, we required the formation of an initial allylic cation. To this end, *n*-pentenyl ethers (1, X=O-pentenyl), which previously have been employed by the group of Fraser-Reid as glycolysating agent in the presence of I⁺, were explored.² In essence, the *n*-pentenyl group would serve as a dual purpose: initially as an O-protecting group, and eventually as a switch for the generation of an allylic cation on subjection to iodonium ions.

We wish to report our studies in this line and the unexpected findings that compounds of the type 1 ($Y \neq H$) lead to the stereospecific formation of optically active tetrahydrofurans and dihydropyrans.

The required *n*-pentenyl ether 8 was easily obtained in four steps. Alkylation of racemic butyn-3-ol 4 with 1-tosyloxypenten-2-ene gave *n*-pentenyl ether 5. Subsequent conversion to its corresponding alanate and treatment with 1-benzyloxy-2(*S*)-3(*S*)-epoxybutane³ in the presence of $\text{BF}_3 \cdot \text{OEt}_2$,⁴ afforded alcohol 6 as a 1:1 diastereomeric mixture, in 80% yield. Hydrostannylation⁵ provided the *trans* alkene 7 in 84% yield, which was eventually transformed quantitatively to its BOC ester 8, thus setting the stage for the allylic transposition studies.⁶


Scheme 2



a) HNA, 1.2 eq, DMF, 0°C, 20 min, then 1-tosyloxypenten-2-ene, 1.2 eq, 0°C to rt, overnight, quantitative; b) *n*-BuLi, 1 eq, -78°C, 10 min, then MeAl_3 , 1 eq, -35°C, 1 h, then, -78°C, 1-benzyloxy-2(*S*),3(*S*)-epoxybutane, 1 eq, 10 min, then $\text{BF}_3 \cdot \text{OEt}_2$, 1 eq, -78°C, 1 h, 80%; c) *n*-Bu₃SnH, neat, 1 eq, AIBN, catalytic, 120°C, 3 h, 84%; d) *n*-BuLi, 1 eq, 0°C, 10 min, then $(\text{BOC})_2\text{O}$, 1.2 eq, rt, overnight, quantitative.

Treatment of 8 with 4 equivalents of I_2 in acetonitrile, overnight, at room temperature, did not give rise to the expected carbonate, but, instead to the tetrahydrofuran 10, in 86% yield, as single stereomer with respect to the three contiguous chiral centers. Benzyl iodide and 2-iodomethyltetrahydrofuran were also isolated. Cyclisation had apparently occurred with participation of the C(1)-benzyl ether and concomittant loss of CH_2Ph (Scheme 3). Such participation of ether oxygen in iodocyclisation reaction had been previously observed.⁷

Scheme 3




a) I_2 , 4 eq, CH_3CN , NaHCO_3 , excess, rt, overnight, 86%; b) I_2 , 1.5 eq, CH_3CN , NaHCO_3 , excess, -20°C, 15 min, quantitative; c) I(collidine)_2^+ , BF_4^- , 4 eq, CHCl_3 , 0°C, 3 d, 14 70%; d) *n*-BuLi, 3 eq, THF, -78°C, 90%.

On the other hand, examination of vinylstannane 8 by sequential treatment first with 1.5 equivalent of iodine⁸ and then, an iodine free reagent, I(collidine)_2 tetrafluoroborate,⁹ for three days, at room temperature, afforded the cyclic carbonate 11,¹⁰ in 70% yield. Shorter reaction times led to mixtures of 10 and 11. ^1H NMR

analysis of **11** indicated that protons C(1)-H₂ (ABX, δ ppm: 4.24 and 4.49) and C(2)-H (*m*, δ ppm: 5.02) were esterified and not C(4)-H (*d*, δ ppm: 3.2). Information about the stereochemical outcome of the newly formed double bond of **11** was obtained by metallation¹¹ and subsequent protonation supplying a 3:1 mixture of the *trans* and *cis* compounds **12** and **13**, respectively, according to HPLC and ¹H NMR analyses.

In the absence of the BOC ester, subjection of alcohol **7** to first 1.5 equivalent of I₂ to give vinyl iodide **14** and then additional treatment with excess I₂, afforded a 86% yield of tetrahydrofuran **15**.¹² As with carbonate **11**, metallation and subsequent protonation supplied a 3:1 mixture of the *trans* and *cis* compounds **16**¹³ and **17**.¹⁴ Catalytic hydrogenation of both **16** and **17** afforded the same dihydro derivative, ([α]_D = -16.4, CHCl₃, *c* = 0.5). Quite surprising, by the use of I(collidine)₂ perchlorate,⁸ dihydropyran **18**¹⁵ could be isolated in 48% yield. In this case, the C(2)-hydroxyl had attacked at C(6) (Scheme 4).


Scheme 4



a) I₂, 1.5 eq, CH₃CN, NaHCO₃, excess, -20°C, 15 min, quantitative; b) I₂, 4 eq, CH₃CN, NaHCO₃, excess, rt, overnight, 86%; c) *n*-BuLi, 1 eq, THF, -78°C, 3 h, 95%; d) I(collidine)₂⁺ ClO₄⁻, 4 eq, CHCl₃, 0°C, 3 h, 48%.

The relative stereochemistry of the three stereogenic centers in **10**, 2(*R*), 3(*R*), 4(*R*), **15**, 2(*R*), 3(*R*), 4(*R*), and **18**, 2(*R*), 3(*S*), 6(*R*), were unambiguously assigned by the observed nOe interactions, in 2D NOESY experiments, as indicated in Schemes.

Scheme 5



These various results are consistent with attack of C(2)-oxygen on the α -face of the initially allylic carbonium ion **19** to give either oxonium **20** or **21** and which upon debenzoylation with iodide led to **10** or **15** respectively (path A) (Scheme 5).

In the absence of iodide, compound 18, however, could come from 21, *via* allylic substitution at C(6) by the C(2)-hydroxyl, to give the six-membered ring with the given stereochemistry (path B). Similarly, attack of the intermediate 20 by the carbonyl of the BOC group could lead to carbonate 11 of which configuration according to this mechanism has to be 2(*R*), 3(*R*), 4(*R*) (path C) (Scheme 5).

It is not clear as to which mechanism is participating in the stereochemical output of the newly formed double bond.¹⁶ As our starting material is an epimeric mixture at the leaving group center, it will be necessary to examine each epimer separately, to explain these results.

In conclusion, a novel approach to optically active tetrahydrofurans and dihydropyrans, through transposition of allylic *n*-pentenyl ethers has been presented. Further investigations to the generality of this reaction as well as their application to the synthesis of natural products are currently in progress in these laboratories.

References and Notes

- Hoffmann, R.W. *Chem. Rev.*, **1989**, *89*, 1841-1860.
- Zu-Fan, W.; Mootoo, D.R.; Fraser-Reid, B. *Tetrahedron Letters*, **1988**, *29*, 6549-6552; Mootoo, D.R.; Date, V.; Fraser-Reid, B. *J. Amer. Chem. Soc.*, **1988**, *110*, 2662-2663.
- Gao, Y.; Hanson, R.M.; Klunder, J.M.; Ko, S.Y.; Masamune, H.; Sharpless, K.B. *J. Amer. Chem. Soc.* **1987**, *109*, 5765-5780.
- Skrydstrup, T.; Bénéchie, M.; Khuong-Huu, F. *Tetrahedron Letters*, **1990**, *31*, 7145-7148.
- Nativi, C.; Taddei, A. *J. Org. Chem.*, **1988**, *53*, 820-826.
- Satisfactory spectroscopic data were obtained for all the new compounds.
- Bartlett, P.A.; Myerson, J. *J. Amer. Chem. Soc.*, **1978**, *100*, 3950-3957; Williams, D.R.; White, F.H. *J. Org. Chem.*, **1987**, *52*, 5067-5079.
- Rahm, A.; Pereyre, M. *J. Amer. Chem. Soc.*, **1977**, *99*, 1672-1673.
- Lemieux, R.W.; Morgan, A.R. *Can. J. Chem.*, **1965**, *43*, 2190-2198.
- Compound 11, oil; CIMS: MH^+ 403, peaks at 341, 213; IR $\nu_{cm^{-1}}$: 1795 (C=O), 1653 (C=C), 1157, 1067 (C-O); 1H NMR, 250 MHz, $CDCl_3$, δ ppm: 0.86 (3H, d, $J=7$ Hz, C(8)-H₃), 1.92 (3H, d, $J=6$ Hz, C(7)-H₃), 2.1 (1H, m, C(3)-H), 3.2 (1H, $J=6$ Hz, C(4)-H), 4.14 and 4.24 (2H, ABX, $J=8$, $J'=$, C(1)-H₂), 4.2 (1H, m, C(6)-H), 4.49 (2H, AB, $J=10$ Hz, OCH_2Ph), 5.02 (1H, dt, $J=5$ Hz, $J'=8$ Hz, C(2)-H), 6.1 (1H, q, $J=7$ Hz, C-6H), 7.3 (5H, broad s, Ar); ^{13}C NMR, $CDCl_3$, δ ppm: 10.1 (C-8), 21.6 (C-7), 41.9 (C-3), 69.0 (C-1), 70.3 (OCH_2Ph), 76.9 (C-2), 76.8 (C-6), 86.0 (C-4), 113.1 (C-5), 128.1 (ArCH), 128.3 (ArCH), 128.6 (ArCH), 137.2 (C-10), 137.6 (ArC), 156.7 (C=O).
- Schlosser, M.; Hammer, E. *Helv. Chem. Acta*, **1974**, *103*, 2744-2753; Millon, J.; Lorne, G.; Linstrumelle, G. *Synthesis*, **1975**, 434-435.
- Compound 15, oil, EIMS: M^+ 268, m/z 197, 141; 1H NMR, 250 MHz, $CDCl_3$, δ ppm: 1.0 (3H, d, $J=7$ Hz, C(8)-H₃), 1.7 (3H, d, $J=6$ Hz, C(7)-H₃), 2.0 (1H, m, C(3)-H), 3.4 (1H, d, $J=7$ Hz C(4)-H), 3.8 (3H, m, C-2H, C(1)-H₂), 6.0 (1H, q, $J=6$ Hz, C(6)-H); ^{13}C NMR, $CDCl_3$, δ ppm: 15.0 (C-7), 21.5 (C-8), 48.2 (C-3), 73.9 (C-1), 78.9 (C-2), 91.2 (C-4), 113.0 (C-6), 132.7 (C-5).
- Compound 16, $[\alpha]_D^{25} +29.1$, $CHCl_3$, $c=0.59$, 1H NMR: C(5)-H at 5.5 ppm, ddd, $J=15$ Hz, $J'=7$ Hz, $J''=2$ Hz, C(6)-H at 5.7 ppm, dq, $J=15$ Hz, $J'=6$ Hz.
- Compound 17, $[\alpha]_D^{25} -64.4$, $CHCl_3$, $c=0.58$, 1HNMR : C(5)-H and C(6)-H at 5.1 ppm.
- Compound 18, oil, $[\alpha]_D^{25} +71.3$, $CHCl_3$, $c=1.43$; EIMS: M^+ 358, m/z 267, 231, 208; 1H NMR, 250 MHz, $CDCl_3$, δ ppm: 0.9 (3H, d, $J=7$ Hz, C(8)-H₃), 1.4 (3H, d, $J=6$ Hz, C(7)-H₃), 2.1 (1H, m, C(3)-H), 3.4 (2H, ABX, $J_{AB}=10$ Hz, $J_{AX}=6$ Hz, $J_{BX}=7$ Hz, C(1)-H₂), 3.9 (1H, m, C(2)-H), 4.2 (1H, m, C-6H), 4.5 (2H, AB, $J=10$ Hz, OCH_2Ph), 6.4 (1H, d, $J=7$ Hz, C(4)-H), 7.3 (5H, broad s, Ar); ^{13}C NMR, $CDCl_3$, δ ppm: 13.2 (C-7), 22.7 (C-8), 36.3 (C-3), 70.3 (OCH_2Ph), 73.4 (C-1), 74.9 (C-2), 76.8 (C-6), 102.2 (C-5), 127.6 (ArCH), 127.7 (ArCH), 128.3 (ArCH), 136.5 (ArC), 141.9 (C-4).
- Bordwell, F.G. *Accounts Chem. Res.*, **1970**, *3*, 281-290; Stork, G.; White, W.N. *J. Amer. Chem. Soc.*, **1956**, *78*, 4609-4619; Magid, R.M.; Fruchey, O.S. *J. Amer. Chem. Soc.*, **1979**, *101*, 2107-2112; Tanigawa, Y.; Ohta, H.; Sonoda, A.; Murahashi, S.I. *J. Amer. Chem. Soc.*, **1978**, *100*, 4610-4612.

(Received in France 19 July 1993)